Summary
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
History
Aligos Therapeutics was founded in 2017 to develop breakthrough therapies for viral diseases and cancers. Since its inception, the company has built a drug pipeline with the potential to address important unmet medical needs. In addition to partnerships with leading biopharmaceutical companies, Aligos has received grant funding from organizations such as the National Institutes of Health (NIH) and the Michael J. Fox Foundation.
Mission
Aligos’ mission is to develop and commercialize life-changing treatments, leverage our scientific and therapeutic expertise, and unlock the power of great ideas to positively impact patients, their families, and the healthcare system.
Vision
Our vision is to be the leader in developing and commercializing innovative drugs and therapies to improve the lives of patients and their families. We strive to be at the forefront of medical advancement through cutting-edge science, sustainable partnerships, and pioneering collaborations.
Key Team
Ms. Lesley Ann Calhoun CPA (Exec. VP & CFO)
Ms. Lucinda Y. Quan J.D. (Exec. VP, Chief Bus. Officer & Gen. Counsel)
Kristina Engeseth (Exec. Director and Head of People & Culture)
Mr. John Fry (Exec. VP of Clinical Devel.)
Dr. Matthew W. McClure M.D. (Exec. VP & Chief Medical Officer)
Dr. Sushmita M. Chanda DABT, Ph.D. (Exec. VP of Translational Safety Sciences)
Dr. David B. Smith Ph.D. (Exec. VP & Head of Chemical Operations)
Recognition and Awards
Aligos has been awarded a number of prizes and recognition by the industry in recognition of its commitment to patient health, product innovation and corporate responsibility. These include the EU Commission’s Innovation Prize for Europe and the EuroBiotech Emerging Company of the Year .
References
